1-20 of 20
Dennis J. Slamon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

Martina S.J. McDermott, Neil A. O'Brien, Benjamin Hoffstrom, KeWei Gong, Ming Lu, Jun Zhang, Tong Luo, Min Liang, Weiping Jia, Jenny J. Hong, Kevin Chau, Simon Davenport, Bin Xie, Michael F. Press, Richard Panayiotou, Abram Handly-Santana, Joan S. Brugge, Leonard Presta, John Glaspy, Dennis J. Slamon
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (11): 2131–2143.
https://doi.org/10.1158/1078-0432.CCR-22-2981
Published: 01 June 2023
View article titled, Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Open the PDF for Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy

Zev A. Wainberg, Arun S. Singh, Gottfried E. Konecny, Kelly E. McCann, J. Randolph Hecht, Jonathan Goldman, Bartosz Chmielowski, Richard S. Finn, Neil O'Brien, Erika Von Euw, Megan M. Price, Diego Martinez, Lisa Yonemoto, Meghan Brennan, John A. Glaspy, Dennis J. Slamon
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 40–49.
https://doi.org/10.1158/1078-0432.CCR-22-1553
Published: 04 January 2023
View article titled, Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
Open the PDF for Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

Massimo Cristofanilli, Hope S. Rugo, Seock-Ah Im, Dennis J. Slamon, Nadia Harbeck, Igor Bondarenko, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Hiroji Iwata, Ben O'Leary, Fabrice André, Sibylle Loibl, Eustratios Bananis, Yuan Liu, Xin Huang, Sindy Kim, Maria Jose Lechuga Frean, Nicholas C. Turner
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3433–3442.
https://doi.org/10.1158/1078-0432.CCR-22-0305
Published: 15 August 2022
View article titled, Overall Survival with Palbociclib and Fulvestrant in Women with HR<sup>+</sup>/HER2<sup>−</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
Open the PDF for Overall Survival with Palbociclib and Fulvestrant in Women with HR<sup>+</sup>/HER2<sup>−</sup> ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study in another window
Includes: Supplementary data
Journal Articles

Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer

Parvin F. Peddi, Peter A. Fasching, Duan Liu, Emmanuel Quinaux, Nicholas J. Robert, Vicente Valero, John Crown, Carla Falkson, Adam Brufsky, Julie M. Cunningham, Richard M. Weinshilboum, Tadeusz Pienkowski, Wolfgang Eiermann, Miguel Martín, Valerie Bee, Xiaoyan Wang, Liewei Wang, Eric Yang, Dennis J. Slamon, Sara A. Hurvitz
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (9): 1854–1862.
https://doi.org/10.1158/1078-0432.CCR-21-1762
Published: 02 May 2022
View article titled, Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer
Open the PDF for Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Tao Wang, Susan G. Hilsenbeck, Matteo Benelli, Ilenia Migliaccio, Cristina Guarducci, Luca Malorni, Lacey M. Litchfield, Jiangang Liu, Joshua Donaldson, Pier Selenica, David N. Brown, Britta Weigelt, Jorge S. Reis-Filho, Ben H. Park, Sara A. Hurvitz, Dennis J. Slamon, Mothaffar F. Rimawi, Valerie M. Jansen, Rinath Jeselsohn, C. Kent Osborne, Rachel Schiff
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4870–4882.
https://doi.org/10.1158/1078-0432.CCR-19-4191
Published: 01 September 2021
View article titled, Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Open the PDF for Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Tao Wang, Susan G. Hilsenbeck, Matteo Benelli, Ilenia Migliaccio, Cristina Guarducci, Luca Malorni, Lacey M. Litchfield, Jiangang Liu, Joshua Donaldson, Pier Selenica, David N. Brown, Britta Weigelt, Jorge S. Reis-Filho, Ben H. Park, Sara A. Hurvitz, Dennis J. Slamon, Mothaffar F. Rimawi, Valerie M. Jansen, Rinath Jeselsohn, C. Kent Osborne, Rachel Schiff
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4939.
https://doi.org/10.1158/1078-0432.CCR-21-2431
Published: 01 September 2021
View article titled, Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Open the PDF for Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer in another window
Journal Articles

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer

Sara A. Hurvitz, Miguel Martin, Michael F. Press, David Chan, María Fernandez-Abad, Edgar Petru, Regan Rostorfer, Valentina Guarneri, Chiun-Sheng Huang, Susana Barriga, Sameera Wijayawardana, Manisha Brahmachary, Philip J. Ebert, Anwar Hossain, Jiangang Liu, Adam Abel, Amit Aggarwal, Valerie M. Jansen, Dennis J. Slamon
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (3): 566–580.
https://doi.org/10.1158/1078-0432.CCR-19-1425
Published: 03 February 2020
View article titled, Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer
Open the PDF for Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR<sup>+</sup>/HER2<sup>−</sup> Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer

Richard S. Finn, Yuan Liu, Zhou Zhu, Miguel Martin, Hope S. Rugo, Véronique Diéras, Seock-Ah Im, Karen A. Gelmon, Nadia Harbeck, Dongrui R. Lu, Eric Gauthier, Cynthia Huang Bartlett, Dennis J. Slamon
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (1): 110–121.
https://doi.org/10.1158/1078-0432.CCR-19-0751
Published: 03 January 2020
View article titled, Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer
Open the PDF for Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

Howard M. Stern, Humphrey Gardner, Tomasz Burzykowski, Wafaa Elatre, Carol O'Brien, Mark R. Lackner, Gary A. Pestano, Angela Santiago, Ivonne Villalobos, Wolfgang Eiermann, Tadeusz Pienkowski, Miguel Martin, Nicholas Robert, John Crown, Paolo Nuciforo, Valerie Bee, John Mackey, Dennis J. Slamon, Michael F. Press
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (9): 2065–2074.
https://doi.org/10.1158/1078-0432.CCR-14-2993
Published: 30 April 2015
View article titled, PTEN Loss Is Associated with Worse Outcome in <em>HER2</em>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
Open the PDF for PTEN Loss Is Associated with Worse Outcome in <em>HER2</em>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance in another window
Includes: Supplementary data
Journal Articles

Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

Neil A. O'Brien, Karen McDonald, Luo Tong, Erika von Euw, Ondrej Kalous, Dylan Conklin, Sara A. Hurvitz, Emmanuelle di Tomaso, Christian Schnell, Ronald Linnartz, Richard S. Finn, Samit Hirawat, Dennis J. Slamon
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (13): 3507–3520.
https://doi.org/10.1158/1078-0432.CCR-13-2769
Published: 01 July 2014
View article titled, Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
Open the PDF for Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT in another window
Includes: Supplementary data
Journal Articles

Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy

Pedro J. Beltran, Frank J. Calzone, Petia Mitchell, Young-Ah Chung, Elaina Cajulis, Gordon Moody, Brian Belmontes, Chi-Ming Li, Steven Vonderfecht, Victor E. Velculescu, Guorong Yang, Jingwei Qi, Dennis J. Slamon, Gottfried E. Konecny
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (11): 2947–2958.
https://doi.org/10.1158/1078-0432.CCR-13-3448
Published: 29 May 2014
View article titled, Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy
Open the PDF for Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

Sara A. Hurvitz, David J. Betting, Howard M. Stern, Emmanuel Quinaux, Jeremy Stinson, Somasekar Seshagiri, Ying Zhao, Marc Buyse, John Mackey, Adrian Driga, Sambasivarao Damaraju, Mark X. Sliwkowski, Nicholas J. Robert, Vicente Valero, John Crown, Carla Falkson, Adam Brufsky, Tadeusz Pienkowski, Wolfgang Eiermann, Miguel Martin, Valerie Bee, Omkar Marathe, Dennis J. Slamon, John M. Timmerman
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (12): 3478–3486.
https://doi.org/10.1158/1078-0432.CCR-11-2294
Published: 14 June 2012
View article titled, Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients
Open the PDF for Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

Gottfried E. Konecny, Boris Winterhoff, Teodora Kolarova, Jingwei Qi, Kanthinh Manivong, Judy Dering, Guorong Yang, Meenal Chalukya, He-Jing Wang, Lee Anderson, Kimberly R. Kalli, Richard S. Finn, Charles Ginther, Siân Jones, Victor E. Velculescu, Darren Riehle, William A. Cliby, Sophia Randolph, Maria Koehler, Lynn C. Hartmann, Dennis J. Slamon
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (6): 1591–1602.
https://doi.org/10.1158/1078-0432.CCR-10-2307
Published: 15 March 2011
View article titled, Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
Open the PDF for Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo

Zev A. Wainberg, Adrian Anghel, Amrita J. Desai, Raul Ayala, Tong Luo, Brent Safran, Marlena S. Fejzo, J. Randolph Hecht, Dennis J. Slamon, Richard S. Finn
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (5): 1509–1519.
https://doi.org/10.1158/1078-0432.CCR-09-1112
Published: 28 February 2010
View article titled, Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab <em>In vitro</em> and <em>In vivo</em>
Open the PDF for Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab <em>In vitro</em> and <em>In vivo</em> in another window
Journal Articles

First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors

Pamela N. Munster, Carolyn D. Britten, Monica Mita, Karen Gelmon, Susan E. Minton, Stacy Moulder, Dennis J. Slamon, Feng Guo, Stephen P. Letrent, Louis Denis, Anthony W. Tolcher
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (4): 1238–1245.
https://doi.org/10.1158/1078-0432.CCR-06-1539
Published: 22 February 2007
View article titled, First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors
Open the PDF for First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors in another window
Journal Articles

Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials

Michael F. Press, Guido Sauter, Leslie Bernstein, Ivonne E. Villalobos, Martina Mirlacher, Jian-Yuan Zhou, Rooba Wardeh, Yong-Tian Li, Roberta Guzman, Yanling Ma, Jane Sullivan-Halley, Angela Santiago, Jinha M. Park, Alessandro Riva, Dennis J. Slamon
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6598–6607.
https://doi.org/10.1158/1078-0432.CCR-05-0636
Published: 15 September 2005
View article titled, Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials
Open the PDF for Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials in another window
Journal Articles

Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development

John W. Park, Robert S. Kerbel, Gary J. Kelloff, J. Carl Barrett, Bruce A. Chabner, David R. Parkinson, Jonathan Peck, Raymond W. Ruddon, Caroline C. Sigman, Dennis J. Slamon
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (11): 3885–3896.
https://doi.org/10.1158/1078-0432.CCR-03-0785
Published: 01 June 2004
View article titled, Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
Open the PDF for Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development in another window
Journal Articles

Association between HER-2/ neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients

Gottfried E. Konecny, Y. Gloria Meng, Michael Untch, He-Jing Wang, Ingo Bauerfeind, Melinda Epstein, Petra Stieber, Jean-Michel Vernes, Johnny Gutierrez, Kyu Hong, Malgorzata Beryt, Hermann Hepp, Dennis J. Slamon, Mark D. Pegram
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (5): 1706–1716.
https://doi.org/10.1158/1078-0432.CCR-0951-3
Published: 10 March 2004
View article titled, Association between HER-2/ <em>neu</em> and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients
Open the PDF for Association between HER-2/ <em>neu</em> and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients in another window
Journal Articles

Treatment of Meningeal Breast Cancer Xenografts in the Rat Using an Anti-P185/HER2 Antibody

Ira Bergman, Mamdouha A. Barmada, Judith A. Griffin, Dennis J. Slamon
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (7): 2050–2056.
Published: 01 July 2001
View article titled, Treatment of Meningeal Breast Cancer Xenografts in the Rat Using an Anti-P185/HER2 Antibody
Open the PDF for Treatment of Meningeal Breast Cancer Xenografts in the Rat Using an Anti-P185/HER2 Antibody in another window
Journal Articles

Effects of SU101 in Combination with Cytotoxic Agents on the Growth of Subcutaneous Tumor Xenografts

Laurie M. Strawn, Fairooz Kabbinavar, Donna P. Schwartz, Elaina Mann, Laura K. Shawver, Dennis J. Slamon, Julie M. Cherrington
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (7): 2931–2940.
Published: 01 July 2000
View article titled, Effects of SU101 in Combination with Cytotoxic Agents on the Growth of Subcutaneous Tumor Xenografts
Open the PDF for Effects of SU101 in Combination with Cytotoxic Agents on the Growth of Subcutaneous Tumor Xenografts in another window